Tokyo University of Science

Written By David Oarr

Through our agreement with the Tokyo University of Science, Division of Molecular Regulation of Inflammation and Immune Diseases, we will investigate and confirm synergies between TNF alpha and existing immunotherapies. Additional research and development work may also be conducted in collaboration with CytImmune on our new second generation immuno-oncology nanomedicines. This work will be completed in the laboratory of Dr. Kouji Matsushima, renowned immunologist and former president of the International Cytokine Society.

David Oarr
Previous

U.S. National Cancer Institute